Who are Abiraterone Acetate or Enzalutamide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abiraterone-acetate-or-enzalutamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Abiraterone Acetate or Enzalutamide — Competitive Intelligence Brief

Abiraterone Acetate or Enzalutamide (Abiraterone Acetate or Enzalutamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen synthesis inhibitor (abiraterone) / Androgen receptor antagonist (enzalutamide). Area: Oncology.

phase 3 Androgen synthesis inhibitor (abiraterone) / Androgen receptor antagonist (enzalutamide) CYP17A1 (abiraterone) / Androgen receptor (enzalutamide) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Abiraterone Acetate or Enzalutamide (Abiraterone Acetate or Enzalutamide) — National Cancer Institute, Naples. Abiraterone acetate inhibits CYP17A1 to block androgen synthesis, while enzalutamide antagonizes the androgen receptor, both reducing androgen-driven prostate cancer growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abiraterone Acetate or Enzalutamide TARGET	Abiraterone Acetate or Enzalutamide	National Cancer Institute, Naples	phase 3	Androgen synthesis inhibitor (abiraterone) / Androgen receptor antagonist (enzalutamide)	CYP17A1 (abiraterone) / Androgen receptor (enzalutamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen synthesis inhibitor (abiraterone) / Androgen receptor antagonist (enzalutamide) class)

National Cancer Institute, Naples · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abiraterone Acetate or Enzalutamide — Competitive Intelligence Brief. https://druglandscape.com/ci/abiraterone-acetate-or-enzalutamide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab